Capsaicin analogs and uses thereof
AssigneeYoung BioPharma, LLC
InventorsYoung Shen, Junke Liu
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising compounds having formulas (I), (II) or and additionally provides methods for the use thereof in the treatment of various disorders including neurological disorders, cancer, diabetes, and obesity, wherein R1-R7, X, A, and Q in (I), R1-R15 in (II) and R1-R15 in (III) are as defined herein. In certain embodiments, methods for the treatment of various disorders including pain and cancer comprise topically, locally or systemically (e.g., IV, IP or orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formulas (I), (II) or (III).
Claims18
A compound having the structure (III) as defined below:
- or pharmaceutically acceptable derivative thereof;
- wherein R1 is hydrogen;
- R2 is hydroxyl, or protected hydroxyl;
- R3 is hydroxyl, protected hydroxyl except for alkoxy, amine or protected amine;
- R4 is hydrogen;
- R5 is hydrogen;
- R6 is hydrogen;
- R7 is hydrogen;
- R8 is hydrogen;
- R9 is hydrogen;
- R10 is hydrogen;
- R11 is hydrogen;
- R12 is hydrogen, or haloalkyl;
- R13 is hydrogen, or haloalkyl;
- R14 is hydrogen, or haloalkyl;
- and
- R15 is hydrogen,
- wherein at least one of R12, R13, or R14 is haloalkyl.
A method for treating a disorder associated with a TRP receptor and/or Src protein, the method comprising increasing, or enhancing, the biological activity of a TRP receptor and/or blocking the activation of Src protein in a subject, by administering to the subject a therapeutically effective amount of a compound having the structure:
- or pharmaceutically acceptable derivative thereof;
- wherein R1 is hydrogen;
- R2 is hydroxyl, or protected hydroxyl;
- R3 is hydroxyl, protected hydroxyl except for alkoxy, amine or protected amine;
- R4 is hydrogen;
- R5 is hydrogen;
- R6 is hydrogen;
- R7 is hydrogen;
- R8 is hydrogen;
- R9 is hydrogen;
- R10 is hydrogen;
- R11 is hydrogen;
- R12 is hydrogen, or haloalkyl;
- R13 is hydrogen, or haloalkyl;
- R14 is hydrogen, or haloalkyl;
- and
- R15 is hydrogen;
- wherein at least one of R12, R13, or R14 is haloalkyl, and wherein the compound activates the TRP receptor and/or blocks the activation of Src protein, thereby treating the disorder.
Dependencies are inferred from the claim text.